Amylyx Pharmaceuticals (AMLX) EBT Margin Growth (1y) (2022 - 2024)
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) EBT Margin Growth (1y) (2022 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | -801,907.00 |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 599,733.00 |
| Sep 30, 2024 | -1.75 Mn |
| Jun 30, 2024 | -713,099.00 |
| Mar 31, 2024 | -13,570.00 |
| Dec 31, 2023 | 20,349.00 |
| Sep 30, 2023 | 1.56 Mn |
| Sep 30, 2022 | -749,768.00 |